Purging leukemia cells from hematopoietic stem cells
    2.
    发明授权
    Purging leukemia cells from hematopoietic stem cells 失效
    从造血干细胞清除白血病细胞

    公开(公告)号:US06461869B1

    公开(公告)日:2002-10-08

    申请号:US09357752

    申请日:1999-07-20

    IPC分类号: C12N1586

    摘要: A gene therapy system is disclosed that selectively kills leukemia cells in bone marrow, while leaving stem cells unaffected. All cells in a mixture of stem cells and leukemia cells are transfected with a high efficiency gene transfer vector. The vector carries a eukaryotic expression construct encoding a toxin gene. This toxin gene is expressed only in leukemia cells, not in stem cells. Differential expression of the toxin gene in leukemia cells and stem cells may be achieved by placing the coding sequence under the control of an appropriate promoter, such as the RSV promoter or the SV40 promoter. High gene expression has been demonstrated in a panel of transformed leukemia cell lines, but no gene expression in transformed, CD34-selected, primary human stem cells. The treatment will be useful not only for leukemia patients, but also for other cancer patients undergoing autologous bone marrow transplants (e.g., breast or lymphoma cancers).

    摘要翻译: 公开了一种基因治疗系统,其选择性地杀死骨髓中的白血病细胞,同时使干细胞不受影响。 用高效率的基因转移载体转染干细胞和白血病细胞混合物中的所有细胞。 载体携带编码毒素基因的真核表达构建体。 这种毒素基因仅在白血病细胞中表达,而不是在干细胞中表达。 毒素基因在白血病细胞和干细胞中的差异表达可以通过将编码序列置于合适的启动子如RSV启动子或SV40启动子的控制下来实现。 已经在一组转化的白血病细胞系中证实了高基因表达,但是在转化的CD34选择的原代人干细胞中没有基因表达。 该治疗不仅对白血病患者有用,而且对于经历自体骨髓移植(例如乳腺癌或淋巴瘤)的其它癌症患者也是有用的。

    Helper adenovirus vectors
    4.
    发明授权
    Helper adenovirus vectors 有权
    辅助腺病毒载体

    公开(公告)号:US06451596B1

    公开(公告)日:2002-09-17

    申请号:US09562919

    申请日:2000-05-02

    IPC分类号: C12N1586

    摘要: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These “gutted” vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.

    摘要翻译: 本发明提供了改进的腺病毒载体和包装细胞系。 一种类型的改良的腺病毒载体包含在腺病毒基因组的E2b区域内的缺失。 这些E2b缺失的病毒与组成型表达E2b基因产物的新型细胞系一起使用。 本发明还提供了所有病毒编码区缺失的腺病毒载体。 这些“内含”载体允许将大基因转移到细胞中,如本文通过将肌营养不良蛋白基因转移到小鼠的肌肉所证明的。 E2b缺失的载体和内切的载体提供了可用于各种基因治疗应用的改良的腺病毒载体。

    Plant pyruvate dehydrogenase kinase gene
    7.
    发明授权
    Plant pyruvate dehydrogenase kinase gene 失效
    植物丙酮酸脱氢酶激酶基因

    公开(公告)号:US06825039B2

    公开(公告)日:2004-11-30

    申请号:US10202428

    申请日:2002-07-23

    IPC分类号: C12N1586

    摘要: The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene (SEQ ID NO:1) (pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size/weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1, or a part of SEQ ID NO:1 characterized in that said sequence has been introduced in an anti-sense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and/or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.

    摘要翻译: 本发明涉及来自十字花科(特别是拟南芥属)的线粒体丙酮酸脱氢酶激酶(PDHK)基因(SEQ ID NO:1)(pYA5; ATCC No 209562)的分离,纯化,表征和应用。 本发明包括所述序列的分离和纯化的DNA,并且涉及调节脂肪酸合成,种子油含量,种子大小/重量,开花时间,营养生长,呼吸速率和使用该基因和组织和植物转化的产生时间的方法 与基因。 本发明还涉及具有包含SEQ ID NO:1的引入的DNA序列或SEQ ID NO:1的部分的基因组的转基因植物,植物组织和植物种子,其特征在于所述序列被引入反义 或感觉取向,以及生产这种植物和植物种子的方法。 本发明还涉及来自编码具有25%或更高同一性的推定的氨基酸序列的蛋白质的植物的基本上同源的DNA序列,以及50%或更多相似性的分离和/或通过使用SEQ ID NO:1的序列信息的已知方法 ,以及通过用于反义,共抑制或其他基因沉默技术仍然能够用作基因表达抑制剂的减少长度的部分。

    Episomal vectors and uses thereof
    10.
    发明授权
    Episomal vectors and uses thereof 有权
    上皮样载体及其用途

    公开(公告)号:US06479279B2

    公开(公告)日:2002-11-12

    申请号:US09101068

    申请日:1998-09-28

    申请人: Mart Ustav

    发明人: Mart Ustav

    IPC分类号: C12N1586

    摘要: The invention relates to a recombinant vector for stable persistence of exogenous DNA in a eukaryotic cell, and the uses of the recombinant vector for long-term stable production of gene product in the host cell, the vector including the minichromosomal maintenance element of papillomavirus.

    摘要翻译: 本发明涉及用于在真核细胞中稳定保持外源DNA的重组载体,以及重组载体用于宿主细胞中基因产物长期稳定产生的用途,载体包括乳头瘤病毒的染色体维持元件。